At the recent NCLifeSci 2025 Annual Meeting, Marcel Frenkel, co-founder and CEO of Ten63 Therapeutics, shared some exciting insights about drug discovery. He discussed how Ten63 aims to tackle a challenging aspect of medicine: the 80% of the human genome known as “undruggable.” Using advanced AI and computational tools, the company is working to develop groundbreaking therapies.
One key focus is on creating new treatments for hard-to-treat conditions like cancer and Ewing sarcoma. This innovative approach has the potential to speed up the drug development process and offer hope to patients who currently have limited options.
AI’s role in drug discovery is increasingly important. Recent studies show that AI can reduce the time it takes to bring new drugs to market. This technology analyzes vast amounts of data quickly, identifying patterns that human researchers might miss. According to a report by the MIT Technology Review, companies using AI for drug discovery saw a 30% faster development rate compared to traditional methods.
These developments are more than just scientific breakthroughs—they represent a shift in how we view treatment possibilities. As Marcel indicated, this could redefine expectations for patients, making once “undruggable” conditions treatable.
As this field grows, people are engaging more with these ideas on social media. Many users are sharing stories of hope and excitement, emphasizing their eagerness for new treatments. This shows a strong connection between scientific advancements and public interest.
For more information, you can check out reports from MIT Technology Review and other trusted sources about advancements in drug discovery.
